Open AccessEndocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
Author(s) -
Xiumei Wang,
Fang Yao,
Wenbo Sun,
Zhi Xu,
Yanyan Zhang,
Xiaowei Wei,
Xiaowen Ding,
Yong Xu
Publication year - 2020
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2020.4990
Subject(s) - prostate cancer , cancer , molecular medicine , relb , carcinogenesis , cancer research , biology , oncogene , hormone , metastasis , breast cancer , mechanism (biology) , oncology , bioinformatics , cell cycle , medicine , endocrinology , transcription factor , nfkb1 , genetics , gene , philosophy , epistemology
Prostate cancer (PCa) and breast cancer (BCa) are two common sex hormone‑related cancer types with high rates of morbidity, and are leading causes of cancer death globally in men and women, respectively. The biological function of androgen or estrogen is a key factor for PCa or BCa tumorigenesis, respectively. Nevertheless, after hormone deprivation therapy, the majority of patients ultimately develop hormone‑independent malignancies that are resistant to endocrinotherapy. It is widely recognized, therefore, that understanding of the mechanisms underlying the process from hormone dependence towards hormone independence is critical to discover molecular targets for the control of advanced PCa and BCa. This review aimed to dissect the important mechanisms involved in the therapeutic resistance of PCa and BCa. It was concluded that activation of the NF‑κB pathway is an important common mechanism for metastasis and therapeutic resistance of the two types of cancer; in particular, the RelB‑activated noncanonical NF‑κB pathway appears to be able to lengthen and strengthen NF‑κB activity, which has been a focus of recent investigations.